Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02319837 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
A Phase 3 study of Prostate Cancer and Cancer of the Prostate, sponsored by Pfizer.
- Active
- Registry status
- Phase 3
- Development phase
- 1,068
- Enrollment target
- 20
- Study locations
NCT02319837 is a Phase 3 study of Prostate Cancer and Cancer of the Prostate that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 1,068 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (76% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT02319837, a Phase 3 study of Prostate Cancer and Cancer of the Prostate, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,068 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both. The randomized / blinded portion of the study is now completed following primary endpoint analyses. The study remains ongoing in open label format.
Conditions Studied
Interventions
- DRUG Enzalutamide
- DRUG Placebo (No longer applicable in Open Label study period)
- DRUG Leuprolide Open Label
Study Locations (20)
California
- Tower Hematology Oncology Medical Group - Beverly Hills
- Cedars-Senai OCC Pharmacy - Los Angeles
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute - Los Angeles
- University of California, Irvine Medical Center - Orange
- Sutter Medical Group, Vascular & Varicose Vein Center - Roseville
- Sutter Medical Group - Roseville
- UC Davis Comprehensive Cancer Center - Sacramento
- University of California Davis Medical Center - Sacramento
- University of California, Davis, School of Medicine - Sacramento
Alabama
- University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham, IDS Pharmacy - Birmingham
- University of Alabama at Birmingham - Birmingham
Colorado
- The Urology Center of Colorado - Denver
- Foothills Urology, P.C. - Golden
Georgia
- Emory University Hospital - Atlanta
- Winship Cancer Institute, Emory University - Atlanta
Alaska
- Alaska Urological Institute dba Alaska Clinical Research Center - Anchorage
Arizona
- Urological Associates of Southern Arizona, PC - Tucson
Connecticut
- Eastern Connecticut Hematology Oncology Associates - Norwich
Florida
- Lakeland Regional Health Hollis Cancer Center - Lakeland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,068 participants |
| Start Date | 2014-12-17 |
| Est. Completion | 2026-09-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02319837
The ClinicalTrials.gov registry entry for NCT02319837 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,068 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (76% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Enzalutamide is the first listed.
NCT02319837 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Alabama, Colorado.
Frequently Asked Questions
What is clinical trial NCT02319837 about?
NCT02319837 is a clinical study titled "Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)". The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both. The randomized / blinded portion of the study is now completed following primary endpoint analyses. The study...
What is the current status of trial NCT02319837?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,068 participants. The study started on 2014-12-17. Estimated completion is 2026-09-19.
What conditions does trial NCT02319837 study?
This clinical trial studies the following conditions: Prostate Cancer, Cancer of the Prostate, Hormone Sensitive Prostate Cancer.
What interventions are being tested in trial NCT02319837?
The interventions under investigation include: Enzalutamide (DRUG), Placebo (No longer applicable in Open Label study period) (DRUG), Leuprolide Open Label (DRUG).
Who is sponsoring clinical trial NCT02319837?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02319837 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.